$193 Million is the total value of Asymmetry Capital Management, L.P.'s 29 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 433.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SHC | New | SOTERA HEALTH CO | $11,663,000 | – | 467,277 | +100.0% | 6.03% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $11,573,000 | – | 53,855 | +100.0% | 5.99% | – |
| ADPT | New | ADAPTIVE BIOTECHNOLOGIES | $11,574,000 | – | 287,490 | +100.0% | 5.99% | – |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $11,320,000 | +45.5% | 163,135 | +61.1% | 5.86% | +65.1% |
| UNH | New | UNITEDHEALTH GROUP INC | $10,923,000 | – | 29,357 | +100.0% | 5.65% | – |
| AZN | New | ASTRAZENECA PLC-SPONS ADRadr | $10,885,000 | – | 218,918 | +100.0% | 5.63% | – |
| EPIX | New | ESSA PHARMA INC | $8,264,000 | – | 284,459 | +100.0% | 4.28% | – |
| JNCE | New | JOUNCE THERAPEUTICS INC | $5,349,000 | – | 520,858 | +100.0% | 2.77% | – |
| ASLN | New | ASLAN PHARMACEUTICALS LT-ADRadr | $4,531,000 | – | 1,352,577 | +100.0% | 2.34% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $4,156,000 | – | 24,263 | +100.0% | 2.15% | – |
| RNLX | New | RENALYTIX AI PLC-ADRadr | $4,130,000 | – | 160,969 | +100.0% | 2.14% | – |
| PMVP | Buy | PMV PHARMACEUTICALS INC | $3,885,000 | -34.6% | 118,128 | +22.3% | 2.01% | -25.8% |
| MREO | Buy | MEREO BIOPHARMA GROUP PL-ADR | $3,583,000 | +35.3% | 1,063,264 | +43.7% | 1.85% | +53.4% |
| RGLS | New | REGULUS THERAPEUTICS INC | $3,097,000 | – | 1,985,472 | +100.0% | 1.60% | – |
| SEEL | New | SEELOS THERAPEUTICS INC | $2,199,000 | – | 440,745 | +100.0% | 1.14% | – |
| TPTX | New | TURNING POINT THERAPEUTICS I | $1,123,000 | – | 11,873 | +100.0% | 0.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.